Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Li Lab of Computational Cancer Immunology

ElevateBio is a technology-driven genetic medicines company, accelerating access to cutting-edge technologies, end-to-end manufacturing capabilities, and expertise to advance the cell and gene therapy industry. The company's integrated ecosystem of technologies and capabilities enables the discovery, development, manufacturing, and commercialization of a broad spectrum of cell and gene therapies and regenerative medicines.

Clare Murray

ElevateBio

Affimed is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies using its ROCK® (Redirected Optimized Cell Killing) platform.

Affimed

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Metric
Company Name	Li Lab of Computational Cancer Immunology	ElevateBio	Affimed	Alaunos Therapeutics, Inc.
Symbol				TCRT
MSH ID	ORG:LILAB-UTSW	BIO:ELEVATE	COM:AFFIMED	COM:ALAUNOS
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	DE	US
Stage		Series D
Employee Count		462	105	1
Website	lilab-utsw.org	elevate.bio	affimed.com	alaunos.com
LinkedIn		elevatebio	affimed-ag
Founders

Metric
Market Cap		9.61M
Enterprise Value
Monthly Web Traffic	7.15K
Web Traffic Growth	-0.51
Valuation
Raised Capital	401M

Metric
Revenue				5K
Revenue (LTM)
Revenue (NTM)
Gross Profit				-4.80M
EBITDA				-34.27M
Operating Income				-34.27M
Net Income				-35.14M
EPS				-0.00
Diluted EPS				-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				-217
Operating Profit Margin				-2.32K
EBITDA Margin				-6.85K
Net Profit Margin				-2.43K
Return on Equity				-1.41
Return on Assets				-1.87
Return on Capital Employed				-2.36

LILA

ORG:LILAB-UTSW

Li Lab of Computational Cancer Immunology

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-14.38
P/B Ratio				37.65
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				4.36K
EV Multiple				-0.43

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding				0.00
Operating Cycle				243.33
Cash Conversion Cycle				141.48
Asset Turnover				0.00

Metric
Operating Cash Flow				-30.14M
Free Cash Flow				-30.34M
Cash Flow to Debt
Operating Cash Flow/Sales				-1.99K
Free Cash Flow Yield				-0.86

Metric
Cash & Equivalents				6.06M
Accounts Receivable				3K
Inventory
Goodwill
Debt to Capitalization				0.08
Debt to Assets				0.06
Current Ratio				2.75
Quick Ratio				5.16

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				228.47
R&D to Revenue				1.40K
SG&A to Revenue				1.30K